Wednesday, September 10, 2025, Auditorium A1
City centre campus, Tampere University, Kalevantie 4, 33100 Tampere
ISSCD Tampere Satellite Symposiums, detailed programme in here
18.30 – 20.30 Get together in Café & Aula Toivo
Thursday, September 11, 2025, Jarmo Visakorpi Auditorium
Kauppi campus, Tampere University, Arvo Ylpön katu 34, 33520 Tampere
Opening session, Jarmo Visakorpi Auditorium, OPEN FOR ALL
09.00 – 09.10 Opening words – Kalle Kurppa
09.10 – 09.20 5th Maki Celiac Disease Tampere Prize announcement
Vice President Tapio Visakorpi, Tampere University, Finland
09.20 – 09.50 Prize lecture – Awardee
09.50 – 10.20 Keynote lecture: Integrating Type 1 Diabetes and Celiac Disease – Heikki Hyöty
10.20 – 10.50 Coffee break, sponsor exhibition and poster view in “Yellow Hall”
Modeling Celiac Disease for personalized clinical applications – Chairs: Keijo Viiri and Iris Jonkers
10.50 – 11.10 Beyond conventional histology – Kalle Kurppa
11.10 – 11.30 In vitro/preclinical Celiac Disease models – Keijo Viiri
11.30 – 11.50 Omics as personalized clinical tool – Ludvig Sollid
11.50 – 12.00 Oral selected from abstract submissions
A Renormalization-based Composite Scoring Framework Integrating Histologic and Biomarker Indicators in Celiac Disease – Jack Syage, ZymagenX, Inc
Factors modifying Celiac Disease risk and phenotype – Chairs: Kati Juuti-Uusitalo and Elena Verdu
12.10 – 12.30 Genetic background of Celiac Disease: current knowledge – Iris Jonkers
12.30 – 12.50 Microbes as Celiac Disease modifiers – Elena Verdu
12.50 – 13.10 Insights from birth cohort studies – Daniel Agardh
13.10 – 13.30 Orals selected from abstract submissions
The lncRNA MAPKAPK5-AS1 modulates T cell activation and protects from intestinal damage in Celiac Disease – Ainara Castellanos-Rubio, UPV-EHU, Spain
Disruption of energy, amino acids and lipids metabolism in the small intestine contribute to celiac disease pathology – Marijn Berg, University Medical Center Groningen
13.30 – 14.20 Lunch at restaurant area, sponsor and poster exhibition in “Yellow Hall”
Clinical heterogeneity of Celiac Disease – Chairs: Teea Salmi and Alberto Rubio-Tapia
14.20 – 14.40 Diverse clinical presentation of Celiac Disease – Peter Green
14.40 – 15.00 Dermatitis herpetiformis: more than just a skin form of Celiac Disease – Teea Salmi
15.00 – 15.20 Neurological manifestations – Marios Hadjivassiliou
15.20 – 15.40 Orals selected from abstract submissions
Modulation of behavior in gluten challenged humanized NOD-DQ8 mice via intestinal and brain cytokine and neurotransmitter expression and confirmatory duodenal transcriptome changes in the human CEC-3 clinical trial – Aline Pesi, University Medical Center Mainz, Germany
Unveiling heterogenous clinical phenotypes from bulk transcriptomics data in Dermatitis Herpetiformis – Helka Kaunisto, Celiac Disease Research Center, Faculty of Medicine and Health Technology, Tampere, Finland
15.40 – 16.10 Coffee break, sponsor and poster exhibition in “Yellow Hall”
Long-term consequences of Celiac Disease – Chairs: Knut Lundin and Camilla Pasternack
16.10 – 16.30 Long-term complications: focus on liver, bone, and reproductive issues
Alberto Rubio-Tapia
16.30 – 16.50 Mortality trends across different Celiac Disease phenotypes – Joseph A. Murray
16.50 – 17.20 Orals selected from abstract submissions
5-year follow-up on a randomized controlled trial with a low FODMAP diet in treated celiac patients – Frida van Megen, Department of Nutrition, Institute of Basic Medical Sciences, University of Oslo, Norway
Socioeconomic factors associated with greater burden of celiac disease: Results from a nationwide survey of Canadians – James King, University of Calgary, Canada
Population Screening for Celiac Disease and Gluten-free Diet Reduce the Incidence od Subsequent Type-1-Diabetes – Ilma Korponay-Szabo, Heim Pal National Pediatric Institute, Budapest and University of Debrecen, Hungary
17.30 – 18.30 Poster rounds, social, wine and cheese in “Yellow Hall”
20.00 – 24.00 Dinner, Festival Hall Konsu, Puistotorni, Hämeenpuisto 28, Tampere
Friday, September 12, 2025 – Jarmo Visakorpi Auditorium
Kauppi campus, Tampere University, Arvo Ylpön katu 34, 33520 Tampere
Personalized prevention and treatment – Chairs: Juha Taavela and Jason Tye-Din
8.30 – 8.50 The need for novel treatments and an overview of current development
Michael Schumann
8.50 – 9.10 Refractory Celiac Disease – Luca Elli
9.10 – 9.30 Duodenal biopsy pathology for celiac drug trials – Jorma Isola
9.30 – 9.50 Pharmacological studies in celiac disease: endpoints and pitfalls – Detlef Schuppan
9.50 – 10.10 Harnessing T Cell Assays to guide therapy in celiac disease – Jason Tye-Din
10.10 – 10.40 Orals selected from abstract submissions
Regulatory T cells engineered with a gliadin-specific T cell receptor as a therapeutic approach for celiac disease – Olivier Herbin, Regeneron pharmaceuticals
FB102 prevents histological damage and mitigates gluten challenge-induced symptoms in a celiac disease phase 1b study – Jason Tye-Din, Walter and Eliza Hall Institute; Royal Melbourne Hospital
Safety, tolerability and pharmacodynamic effects of TPM502, a mixture of tolerizing
nanoparticles for the treatment of celiac disease – Cristina de Min, Topas Therapeutics
GmbH
10.40 – 11.10 Coffee break, sponsor and poster viewing in “Yellow Hall”
Best practices in monitoring Celiac Disease – Chairs: Laura Kivelä and Luca Elli
11.10 – 11.30 Who will manage all adult Celiac Disease patients – Katri Kaukinen
11.30 – 11.50 Follow-up in childhood – Valentina Discepolo
11.50 – 12.10 Transition in Celiac Disease – Laura Kivelä
12.10 – 12.30 Orals selected from abstract submissions
Reported follow-up status impacts dietary adherence and gastrointestinal symptoms in Norwegian children and adolescents with celiac disease – Therese Margrethe Lysell Lensnes, Department of Pediatric Medicine, Oslo University Hospital
Frequency of follow-up testing for tissue transglutaminase antibodies after initial positivity among children: An analysis of real-world data from a population-based cohort in Canada – James King, University of Calgary, Canada
Closing session – Chairs: Katri Lindfors
12.30 – 12.45 Wrap up of the meeting: Where do we stand in 2025? – Knut Lundin
12.45 – 12.55 Best Abstract of the Symposium Prize – Katri Lindfors
12.55 – 13.05 Closing words – Katri Kaukinen
13.05 – 14.30 Farewell lunch at restaurant area